Bioequivalence study of two capsule formulations of omeprazole. 1996

G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
Faculty of Pharmacy, Jordan University of Science and Technology, Irbid-Jordan.

Bioequivalency of Omeraz, a test-product of Arab Pharmaceutical Manufacturing Company (Jordan) and Losec, a reference product by Astra (Sweden), was evaluated by a randomised crossover study on 22 healthy male volunteers. Serum concentrations of omeprazole were measured by an HPLC assay. There were no statistically significant differences between the two products in terms of serum profile and pharmacokinetic parameters including AUC, Cmax, Tlag, Tmax, MRT, Ke and T1/2. The AUC ratios (Omeraz/Losec) for 24 hours and for infinity were respectively 1.02 with a 90% C.L. of 0.88-1.16 and 1.00 with a 90% C.L. of 0.88-1.14. The two products may be considered as bioequivalent in terms of the extent of absorption as indicated by the AUC ratios. However, the confidence limits of Cmax fall outside the FDA accepted range.

UI MeSH Term Description Entries
D008297 Male Males
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002214 Capsules Hard or soft soluble containers used for the oral administration of medicine. Capsule,Microcapsule,Microcapsules
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies
D018592 Cross-Over Studies Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed) Cross-Over Design,Cross-Over Trials,Crossover Design,Crossover Studies,Crossover Trials,Cross Over Design,Cross Over Studies,Cross Over Trials,Cross-Over Designs,Cross-Over Study,Crossover Designs,Crossover Study,Design, Cross-Over,Design, Crossover,Designs, Cross-Over,Designs, Crossover,Studies, Cross-Over,Studies, Crossover,Study, Cross-Over,Study, Crossover,Trial, Cross-Over,Trial, Crossover,Trials, Cross-Over,Trials, Crossover

Related Publications

G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
January 2008, Arzneimittel-Forschung,
G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
January 2007, Arzneimittel-Forschung,
G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
January 2009, Arzneimittel-Forschung,
G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
November 2016, International journal of clinical pharmacology and therapeutics,
G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
January 2004, International journal of clinical pharmacology and therapeutics,
G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
January 2009, Arzneimittel-Forschung,
G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
March 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
November 2006, International journal of clinical pharmacology and therapeutics,
G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
January 2006, Arzneimittel-Forschung,
G K Pillai, and M S Salem, and N M Najib, and J Jilani, and M M Hasan, and E Ghanem, and E Sallam, and M S Shubair, and S al-Delq
January 2007, Arzneimittel-Forschung,
Copied contents to your clipboard!